BROADCASTS.com

Amir Jafri is the CEO and Founder of Immunicom, targeting the molecules and proteins produced by cancer. Using a subtractive approach, Immunicom has developed technology intended to remove the elements that are suppressing the immune system and allowing the tumor to shield itself from the immune system. After treatment, patients in clinical trials are seeing immune cells infiltrate their solid tumor cancers.

Amir explains, "What we will do is then design our own molecules that will neutralize what the molecule of cancer is producing. But instead of making our molecule into a drug, which is normally what would happen, we actually put it into this proprietary liquid cartridge that we have. It's got a liquid chemical matrix, and there's like a little cartridge, and our molecule goes in there. That cartridge attaches to what's called a plasmapheresis machine."

"Now, that machine is very similar to a dialysis machine. These machines exist all over the world and they've been around for 30 years. The patient sits down, and their blood and plasma attach to the machine. They just sit in a comfortable chair, and their plasma is then taken by the machine and sent through our cartridge. And then we will pull out, in a very, very exquisite way, the molecule that the cancer is producing that is suppressing the immune system."

@Immunicom #ImmuneSystem #Immunotherapy #MedicalDevice #HealthTech #MedTech #Oncology #Cancer #Tumors

Immunicom.com

Download the transcript here